Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study

被引：0

作者：

Wolin, Edward M. ^{[1
]}

Pavel, Marianne E. ^{[2
]}

Cwikla, Jaroslaw B. ^{[3
]}

Phan, Alexandria T. ^{[4
]}

Raderer, Markus ^{[5
]}

Sedlackova, Eva ^{[6
,7
]}

Cadiot, Guillaume ^{[8
]}

Capdevila, Jaume ^{[9
]}

Wall, Lucy ^{[10
]}

Rindi, Guido ^{[11
]}

Lombard-Bohas, Catherine ^{[12
]}

Liyanage, Nilani ^{[13
]}

Thanh, Xuan-Mai Truong ^{[14
]}

Ruszniewski, Philippe B. ^{[15
]}

Caplin, Martyn E. ^{[16
]}

Investigators, Clarinet ^{[17
]}

机构：

[1] Montefiore Einstein Ctr Canc Care, New York, NY USA

[2] Univ Klinikum Erlangen, Erlangen, Germany

[3] Univ Warmia & Mazury, Olsztyn, Poland

[4] Canc Treatment Ctr Amer, Atlanta, GA USA

[5] Univ Hosp, Vienna, Austria

[6] First Fac Med, Prague, Czech Republic

[7] Gen Teaching Hosp, Prague, Czech Republic

[8] Robert Debre Hosp, Reims, France

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Hosp Civils Lyon, Edouard Herriot Hosp, Lyon, France

[13] Ipsen, Les Ulis, France

[14] Ipsen, Boulogne, France

[15] Beaujon Hosp, Clichy, France

[16] Royal Free Hosp, London, England

[17] CLARINET Study Investigators, London, England

来源：

PANCREAS | 2018年 / 47卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：358 / 359

页数：2

共 50 条

[1] Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.
Wolin, Edward M.
Pavel, Marianne
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Lombard-Bohas, Catherine
Liyanage, Nilani
Mai, Xuan
Thanh, Truong
Ruszniewski, Philippe
Caplin, Martyn E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
Caplin, Martyn E.
Ruszniewski, Philippe B.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wall, Lucy R.
Rindi, Guido
Langley, Alison
Blumberg, Joelle
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
Caplin, Martyn E.
Pavel, Marianne
Phan, Alexandria T.
Cwikla, Jaroslaw B.
Sedlackova, Eva
Thanh, Xuan-Mai Truong
Wolin, Edward M.
Ruszniewski, Philippe
ENDOCRINE, 2021, 71 (02) : 502 - 513
[4] Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
Martyn E. Caplin
Marianne Pavel
Alexandria T. Phan
Jarosław B. Ćwikła
Eva Sedláčková
Xuan-Mai Truong Thanh
Edward M. Wolin
Philippe Ruszniewski
Endocrine, 2021, 71 : 502 - 513
[5] Lanreotide Depot/Autogel in Neuroendocrine Tumors: Subgroup Analyses From the CLARINET Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 6 - 8
[6] Multivariate Analysis of Progression-Free Survival in the CLARINET Study of Lanreotide Autogel/Depot vs Placebo Identifies Prognostic Factors in Neuroendocrine Tumors
Wolin, Edward M.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
PANCREAS, 2016, 45 (03) : 486 - 486
[7] Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study
Caplin, Martyn E.
Phan, Alexandria T.
Ruszniewski, Philippe
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
PANCREAS, 2015, 44 (02) : 351 - 352
[8] Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120 mg in the CLARINET open-label extension
Pavel, M.
Cwikla, J.
Wolin, E.
Phan, A.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Capdevila, J.
Rindi, G.
Lombard-Bohas, C.
Liyanage, N.
Thanh, Truong X. -M
Ruszniewski, P.
Caplin, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 310 - 310
[9] Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).
Wolin, Edward M.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension
Cwikla, J. B.
Wolin, E. M.
Pavel, M.
Phan, A. T.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Capdevila, J.
Rindi, G.
Lombard-Bohas, C.
Liyanage, N.
Thanh, X-M. Truong
Ruszniewski, P.
Caplin, M.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →